Does APIXABAN Cause Second primary malignancy? 20 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 20 reports of Second primary malignancy have been filed in association with APIXABAN (ELIQUIS). This represents 0.0% of all adverse event reports for APIXABAN.
20
Reports of Second primary malignancy with APIXABAN
0.0%
of all APIXABAN reports
18
Deaths
19
Hospitalizations
How Dangerous Is Second primary malignancy From APIXABAN?
Of the 20 reports, 18 (90.0%) resulted in death, 19 (95.0%) required hospitalization, and 19 (95.0%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for APIXABAN. However, 20 reports have been filed with the FAERS database.
What Other Side Effects Does APIXABAN Cause?
Death (18,501)
Cerebrovascular accident (7,237)
Atrial fibrillation (5,690)
Off label use (5,590)
Thrombosis (5,298)
Fall (5,063)
Cardiac disorder (4,917)
Haemorrhage (4,770)
Dyspnoea (4,379)
Gastrointestinal haemorrhage (4,030)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which APIXABAN Alternatives Have Lower Second primary malignancy Risk?
APIXABAN vs APOMORPHINE
APIXABAN vs APRACLONIDINE
APIXABAN vs APREMILAST
APIXABAN vs APREPITANT
APIXABAN vs APROTININ